ABBOTT LABORATORIES— Sankey Diagram
Annual mode · period ending 2026-03-31 · SEC EDGAR
FY2026 - Q4(Jan 26 · Feb 26 · Mar 26)
Total Assets
$110.43B
↑+35.6% +$28.98Bvs FY2025
Total Liabilities
$18.38B
↑+41.3% +$5.37Bvs FY2025
Equity
$52.06B
↑+6.7% +$3.25Bvs FY2025
Cash
$6.80B
↑+4.1% +$271Mvs FY2025
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 | FY2025 |
|---|---|---|
| Total Assets | $110.43B | $81.45B |
| Current Assets | $25.51B | $23.15B |
| Cash | $6.80B | $6.53B |
| ST Investments | $492M | $312M |
| Receivables | $8.21B | $7.33B |
| Inventory | $6.99B | $6.64B |
| Other Current | $3.01B | $2.34B |
| Non-Current Assets | $84.92B | $58.30B |
| PPE | $12.38B | $10.93B |
| Goodwill | $35.22B | $23.36B |
| Intangibles | $17.88B | $6.26B |
| Investments | $1.09B | $907M |
| Other Non-Current | $18.36B | $16.84B |
| Total Liab+Eq | $52.06B | $48.81B |
| Current Liab. | $18.38B | $13.00B |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $18.38B | $13.00B |
| Non-Current Liab. | $0 | $0 |
| Long-Term Debt | $29.64B | $12.74B |
| Other LT Liab. | $0 | $0 |
| Equity | $52.06B | $48.81B |
| Retained Earnings | $49.96B | $47.72B |
| Other Equity | $2.10B | $1.10B |
QuarterCharts · SEC EDGAR data · ABT · Comparing FY2026 vs FY2025